Finance
Alexion Pharmaceuticals reports loss of $1.06 per share
Published in Drug Week, September 8th, 2006
The company also announced that the European Medicines Agency (EMEA) has accepted the company's request for evaluation of its anticipated Marketing Authorization Application (MAA) for Soliris (eculizumab) in PNH under the Accelerated Assessment procedure. Accelerated Assessment is granted for medicinal products of major therapeutic interest and shortens the timeframe for review by the agency. The company further announced that it is on track for submission of both its anticipated Biological License Application (BLA) for Soliris (eculizumab) in PNH in the United...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-09-08)
More Articles from Drug Week
- Drug Delivery
Low temperature sensitive liposome-doxorubicin may improve drug delivery to solid tumors - Drug Development
Human primary renal cells used as model for toxicity assessment of chemotherapeutic drugs - Osteoarthritis
IDEA reports positive phase III results for targeted analgesic IDEA-033 - Pharmacokinetics
Interactions between simvastatin and omega-3-acid ethyl esters were examined - Systemic Lupus Erythematosus
Human Genome Sciences launches phase III clinical development program for LymphoStat-B - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
